Imalia Announces Completion of Clinical Phase of French Pilot Study Evaluating IMA001 in Sickle Cell Disease - Imalia

News -Imalia Announces Completion of Clinical Phase of French Pilot Study Evaluating IMA001 in Sickle Cell Disease

Imalia Announces Completion of Clinical Phase of French Pilot Study Evaluating IMA001 in Sickle Cell Disease

Completion of the clinical phase of the monocentric, prospective, open label pilot study conducted in France of daily dosing of IMA001 in 12 sickle cell disease patients.

Leave a Reply Cancel reply

Subscribe to our newsletter

Related Posts

Imalia to Present Two Abstracts at the 66th American Society of Hematology Annual Meeting

Imalia will present two abstracts at the 66th meeting of the American Society of

December 11, 2024 News

Imalia Reports Initial Proof-of-Concept Data for IMA001 in Sickle Cell Disease Model

Imalia reports initial proof-of-concept data for the effect of IMA001,on the progression of markers

September 23, 2022 News

Imalia Announces Completion of Clinical Phase of French Pilot Study Evaluating IMA001 in Sickle Cell Disease

Completion of the clinical phase of the monocentric, prospective, open label pilot study conducted

June 21, 2024 News

Imalia Demonstrates Protective Effect of IMA001 in Acute Vaso-occlusion Episode in Sickle Cell Disease Mice

Precinical proof-of-concept demonstration of the protective effect of the Administration for 36 days of

April 17, 2024 News

Imalia Announces Completion of Clinical Phase of Indian Randomized Pilot Study on IMA001 in Sickle Cell Disease

Completion of the clinical phase of randomized, double blind, placebo controlled pilot study conducted

November 3, 2024 News

Imalia Launches French Pilot Study of IMA001 in Sickle Cell Disease: Focus on Safety, Tolerability, and Quality of Life

Imalia is conducting in France a second monocentric, prospective, open label pilot study in

April 9, 2023 News

Previous

Next